Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

f clinical data at the European Society of Cardiologists by GlaxoSmithKline on the effect of their selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor, darapladib, on a secondary biological outcome while having no effect on inflammation or LDL-C, provides encouraging validation of the anatomical importance of reducing PLA2 activity in a cardiovascular population," said Dr. Robert S. Rosenson, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research at the University of Michigan. "The on-going FRANCIS trial with varespladib, which is designed to evaluate and repeat the results of previous clinical data from PLASMA and PLASMA2 in an ACS population, should provide additional data on an already validated predictor of cardiovascular risk (LDL-C) coupled with reductions in PLA2."

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, clinically meaningful and statistically significant reductions in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

Presently, the company is conducting the five hundred patient FRANCIS trial (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) to assess the impact of oral varespladib on known biological markers of cardiovascular risk in ACS patients with elevated LDL and CRP. FRANCIS will also provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the six-month trial.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and he
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013   Direct to implant, ... is an appropriate option for many women with ... reduce their breast cancer risk, or with breast ... process and a second surgery to insert permanent ... same surgery as mastectomy can be a medically ...
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
(Date:5/23/2013)...  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) ... development and commercialization of novel bile acid therapeutics to ... today announced that Mark Pruzanski , ... the Deutsche Bank Securities 38th Annual Health Care Conference ... 29, 2013 at 4:10 p.m. ET. About ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
(Date:5/24/2013)... Routinely measuring fractional flow reserve (FFR) using pressure ... chest pain leads to significant changes in the ... results from a study reported at EuroPCR 2013. ... influence management strategy at coronary angiography for diagnosis ... whether routine assessment of FFR in all the ...
(Date:5/24/2013)... France: Transcatheter aortic valve implantation (TAVI) is effective and ... on first results from a multicentre Asian registry reported ... has become a treatment option for selected patients with ... all from North American or European centres," Paul Chiam, ... told the conference. He explained that it is unknown ...
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... Springs, FL (PRWEB) May 24, 2013 The ... present May air dates for Charlotte, North Carolina. It is ... to many Fortune 500 companies. The city is populated with ... healthcare organizations which cover residents in both North and South ... about all things medically-related can tune into WAXN-TV 64 Eyewitness ...
(Date:5/24/2013)... 24, 2013 CBT News.com recently announced the ... the web-based retail automotive industry news organization with 12 years ... excited to join a group that’s so forward-thinking in their ... how online video content is on the rise.” , Atlanta ... business and segued into advertising at Cycle News and Boating ...
Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2
... that may cause premature ovarian failure, or early menopause. The ... say, is a poorly understood condition. ,Premature ovarian failure is ... the United States. It is diagnosed in one out of ... that lack both copies of a gene called FOXO3a, which ...
... people throughout the world who suffer from chronic eczema. ... frequent, unpredictable relapses. It is currently treated in one ... a lower potency preparation upon improvement of the condition ... a maintenance regimen using emollients.// However, neither of these ...
... many of the activities to which you are accustomed to ... to go places that aren’t wheelchair accessible or even standing ... Philadelphia brings paralyzed people a little closer to a normal ... to Les Kirk.,Instead of us doing it by our brain, ...
... -- two of which can cause severe skin damage ... at the University of California, the most dangerous kind ... wavelengths and are primarily responsible for sunburn. Repeated exposure ... system and can lead to melanoma and basal and ...
... to 5,000 children in the United States are on dialysis ... develop kidney failure, which requires dialysis or a transplant. ... young patients and their families.Maya Zarger and her sister Aneka ... months old, Maya has been through more than most kids. ...
... A new study shows women with endometriosis may have ... endocrine, ovarian, non-Hodgkin’s lymphoma and brain cancer. ,Endometriosis is ... uterus is found in other areas. The misplaced tissue ... or other sites outside the uterus.// Endometriosis is the ...
Cached Medicine News:
Inquire...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
... two-stage, oil-sealed, rotary vane vacuum pumps specifically ... pump comes complete with a GBORK (Gas ... Mist Filter (EMF-10). The GBORK allows the ... keep the oil clean without losing oil. ...
... The OFP400 Oil-free Vacuum Pump is designed ... has high chemical resistance, quiet running and eliminates ... require any oil to operate. Less mess, less ... , 4-headed design with chemically resistant solid ETFE ...
Medicine Products: